{
  "docId": "019de070-6ba7-74d1-848b-b84c997820ae",
  "docSlug": "fd4b4c87c265fc439333e9f58c5ae8a7",
  "documentTitle": "Compass Therapeutics | IPO Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 40,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide uses a series of line charts to demonstrate efficacy across different antibody affinities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-6ba7-74d1-848b-b84c997820ae/15",
  "deckHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae",
  "deckJsonHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae.json",
  "deckAnchorHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.85,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Tumor volume over time for Control, CTX-471a, CTX-471b, and CTX-471c",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "384af077-f446-4858-a78e-65d9f079544b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Tumors were allowed to grow to ~500 mm³ before treatment began; Therapeutic model, not a prevention model; Unprecedented Monotherapy activity for an I/O Antibody in these Pre-Clinical Models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9484c9a5-08f2-4fb2-b832-b6a5c5dc0716",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "INTERMEDIATE AFFINITY FOR CD137 INDUCED OPTIMAL ANTI-TUMOR ACTIVITY",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7cdecad-f77f-40f3-bce9-c2dbe4df775a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CTX-471 Induced Complete Regressions of ~500 mm³ CT26 Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d42bed0a-3d1d-4dda-b950-d4d98ffa332b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "f1771169-2b88-46a4-b96f-6f734480b1ff",
      "evidence": "Tumor volume over time chart",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 7,
      "beatId": "4189f97c-14ae-46e9-86c5-8cb495a87bea",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-24: Overview of Compass Proprietary Technologies, Pipeline, and clinical data",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 18,
      "from": 13,
      "beatId": "ec336838-4466-4bc9-8486-b974f1437248",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 13-18: CTX-471, a potential best-in-class CD137 agonist",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8f23aa4f-73de-402c-b124-1353a7937adb",
      "evidence": "The deck presents a clear 'why' throughout, with a focus on the team's expertise and the pipeline's potential",
      "position": 1,
      "objective": "Why Compass Therapeutics, and why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}